Biotechnology company ME Therapeutics Holdings Inc (CSE:METX) (FSE:Q9T) announced on Friday that its subsidiary ME Therapeutics Inc has received a US patent for its lead G-CSF antibody candidate, H1B11-12, covering its amino acid sequence and therapeutic use for cancer treatment.

US Patent No. 12,421,308 marks the company's second international patent for the candidate, following approval from China in 2023. H1B11-12 is a humanised biological drug designed to block G-CSF, a cytokine that drives immune suppression in the tumour microenvironment.

ME Therapeutics is advancing cell line development for the antibody under Good Manufacturing Practices to support clinical trial regulatory submissions. Candidate cell lines have demonstrated strong antibody production and stability, with further testing planned to select a lead clone for a GMP master cell bank.

The company is also progressing its therapeutic mRNA programme, with preclinical studies showing immune cell recruitment into tumours and strong T cell activation in vitro. Planned studies include testing the lead mRNA candidate in a mouse colon cancer model, alone and with immune checkpoint inhibitors.

In addition, the in vivo CAR programme is advancing through discovery, with tumour-targeted CARs demonstrating confirmed in vitro activity ahead of future in vivo testing.

ME Therapeutics continues to expand its research team, adding two associate scientists to accelerate clinical development of the lead antibody and broader cancer programmes.